Amanote Research
Register
Sign In
Cost-Effectiveness of Rivaroxaban for the Treatment of Pulmonary Embolism in Canada
Value in Health
- United Kingdom
doi 10.1016/j.jval.2014.03.684
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
May 1, 2014
Authors
B. Levac
J. Marrie
W. Chin
F. Hassan
L. Bamber
E.J. McLeod
Publisher
Elsevier BV
Related search
LO74: Cost-Effectiveness of Pathways for Diagnosing Pulmonary Embolism in Canada
Canadian Journal of Emergency Medicine
Emergency Medicine
Cost-Effectiveness in Canada of Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndromes
Current Oncology
Oncology
Treatment of Pulmonary Embolism.
BMJ
The Cost-Effectiveness of Dabigatran Etexilate Compared With Rivaroxaban in the Treatment of Acute Venous Thromboembolism in the Uk
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Treatment of Major Pulmonary Embolism.
BMJ
Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Endovascular Treatment of Acute Pulmonary Embolism
Translational Medicine
Short-Term Results of the Pulmonary Embolism Treatment
Zaporozhye Medical Journal
The Cost-Effectiveness of Apixaban Compared to Warfarin, Aspirin, Rivaroxaban and Dabigatran in Ireland
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
